Cleocin Phosphate

clindamycin phosphate · CLINDAMYCIN PHOSPHATE 150 mg/mL · Injection, Solution · Intramuscular; Intravenous · Medical Purchasing Solutions, LLC

NDC 71872-7165-01 · 1 VIAL in 1 BAG / 6 mL in 1 VIAL · NDA · View full market →

The short version

7 companies supply this market — a reasonable cushion if one runs into trouble. It is in shortage right now — FDA lists the reason as “discontinuation of the manufacture of the drug”.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

All Part D pricing →

Matched to CMS's representative package for this drug (NDC 00009-0902-18) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.

ⓘ How this was built

Data sources

CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)

Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of saleⓘ

$0.6876per unit

middle half $0.6780–$0.7252 · 9 plans · Apr 1, 2026

Est. net of rebatesⓘ

$0.4126–$0.5157

brand drug — est. 25-40% rebate off the price at left

Coverage & restrictions

0%of plans cover it

tier 1 · prior auth 0% · step therapy 0% · qty limit 0%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

Where it's made

Medical Purchasing Solutions, LLCUnited States
repack

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

Part D specialty tier
Costs ≥ $950/fill · avg $56.12 per prescription
Biologic (BLA)
Injectable / infused
Orphan-drug exclusivity
REMS program

Regulatory

Application: NDA050441
TE code: AP
Approval date: Jan 1, 1982
Patents / exclusivity: None on file

Shortage history

Planned discontinuation — Cleocin Phosphate, Injection, 300 mg/2 mL (150 mg/mL); 2 mL Vial (NDC 0009-0870-26)Jun 1, 2026
Planned discontinuation — Cleocin Phosphate, Injection, 300 mg/2 mL (150 mg/mL); 2 mL Vial NovaPlus (NDC 0009-3051-02)Jun 1, 2026
Planned discontinuation — Cleocin Phosphate, Injection, 600 mg/4 mL (150 mg/mL); 4 mL Vial (NDC 0009-0775-26)Jun 1, 2026
Planned discontinuation — Cleocin Phosphate, Injection, 600 mg/4 mL (150 mg/mL); 4 mL Vial NovaPlus (NDC 0009-4073-04)Jun 1, 2026
Planned discontinuation — Cleocin Phosphate, Injection, 900 mg/6 mL (150 mg/mL); 6 mL Vial (NDC 0009-0902-18)Jun 1, 2026
Planned discontinuation — Cleocin Phosphate, Injection, 900 mg/6 mL (150 mg/mL); 6 mL Vial NovaPlus (NDC 0009-5095-06)Jun 1, 2026
In shortage now — Cleocin Phosphate, Injection, 300 mg/2 mL (150 mg/mL) (NDC 0009-3051-02)Mar 21, 2023
Discontinuation of the manufacture of the drug
month 42 — 2× the typical 20-month injectable shortage · model puts 31% odds it resolves within 6 months
In shortage now — Cleocin Phosphate, Injection, 600 mg/4 mL (150 mg/mL) (NDC 0009-4073-04)Mar 21, 2023
Discontinuation of the manufacture of the drug
month 42 — 2× the typical 20-month injectable shortage · model puts 31% odds it resolves within 6 months
In shortage now — Cleocin Phosphate, Injection, 900 mg/6 mL (150 mg/mL) (NDC 0009-5095-06)Mar 21, 2023
Discontinuation of the manufacture of the drug
month 42 — 2× the typical 20-month injectable shortage · model puts 31% odds it resolves within 6 months
In shortage now — Cleocin Phosphate, Injection, Cleocin Phosphate 300 mg/2 mL (150 mg/mL) (NDC 0009-0870-26)Mar 21, 2023
Demand increase for the drug
month 42 — 2× the typical 20-month injectable shortage · model puts 31% odds it resolves within 6 months
In shortage now — Cleocin Phosphate, Injection, Cleocin Phosphate 600 mg/4 mL (150 mg/mL) (NDC 0009-0775-26)Mar 21, 2023
month 42 — 2× the typical 20-month injectable shortage · model puts 31% odds it resolves within 6 months
In shortage now — Cleocin Phosphate, Injection, Cleocin Phosphate 900 mg/6 mL (150 mg/mL) (NDC 0009-0902-18)Mar 21, 2023
month 42 — 2× the typical 20-month injectable shortage · model puts 31% odds it resolves within 6 months
In shortage now — Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-02)Mar 21, 2023
Discontinuation of the manufacture of the drug
month 42 — 2× the typical 20-month injectable shortage · model puts 31% odds it resolves within 6 months
In shortage now — Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-04)Mar 21, 2023
Discontinuation of the manufacture of the drug
month 42 — 2× the typical 20-month injectable shortage · model puts 31% odds it resolves within 6 months
In shortage now — Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-06)Mar 21, 2023
Discontinuation of the manufacture of the drug
month 42 — 2× the typical 20-month injectable shortage · model puts 31% odds it resolves within 6 months

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of clindamycin phosphate (Injection, Solution)

Labeler	Strength	First seen	Last seen
Baxter Healthcare Company	CLINDAMYCIN PHOSPHATE 300 mg/50mL	Jul 15, 2026	Sep 3, 2026
Baxter Healthcare Company	CLINDAMYCIN PHOSPHATE 900 mg/50mL	Jul 15, 2026	Sep 3, 2026
Baxter Healthcare Company	CLINDAMYCIN PHOSPHATE 600 mg/50mL	Jul 15, 2026	Sep 3, 2026
Medical Purchasing Solutions, LLC	CLINDAMYCIN PHOSPHATE 150 mg/mL	Jul 15, 2026	Sep 3, 2026
Pharmacia & Upjohn Company LLC	CLINDAMYCIN PHOSPHATE 150 mg/mL	Jul 15, 2026	Sep 3, 2026
Baxter Healthcare Corporation	CLINDAMYCIN PHOSPHATE 600 mg/50mL	Jul 15, 2026	Sep 2, 2026
Baxter Healthcare Corporation	CLINDAMYCIN PHOSPHATE 900 mg/50mL	Jul 15, 2026	Sep 2, 2026
ProPharma Distribution	CLINDAMYCIN PHOSPHATE 150 mg/mL	Jul 15, 2026	Sep 2, 2026
Sagent Pharmaceuticals	CLINDAMYCIN PHOSPHATE 150 mg/mL	Jul 15, 2026	Sep 2, 2026
Henry Schein, Inc.	CLINDAMYCIN PHOSPHATE 150 mg/mL	Jul 15, 2026	Aug 31, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Cleocin Phosphate — NDC 71872-7165-01," retrieved September 3, 2026, https://drugdashboards.com/drug/71872716501.

Free to cite with attribution — see how the data is put together.